SGK1 Overexpression

CI-VAR-00003158Explore in graph →CIViC 693

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm3
SGK1 Overexpression	Alpelisib	Predictive	B	Supports Resistance	3	accepted	EID1730 A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had dise… (full text at CIViC) PMID 27451907 · Castel et al., 2016 · Open in CIViC	civic
SGK1 Overexpression	Alpelisib	Predictive	D	Supports Resistance	5	accepted	EID1729 SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib (NVP-BYL719) in comparison to five sensitive cell lines. Western blots showed c… (full text at CIViC) PMID 27451907 · Castel et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.